Mind Medicine (MindMed) (MNMD) & Its Peers Financial Comparison

Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) is one of 47 public companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Mind Medicine (MindMed) to similar businesses based on the strength of its profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Profitability

This table compares Mind Medicine (MindMed) and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mind Medicine (MindMed) N/A -55.27% -51.10%
Mind Medicine (MindMed) Competitors -187.52% -270.08% -14.90%

Earnings & Valuation

This table compares Mind Medicine (MindMed) and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mind Medicine (MindMed) N/A -$93.04 million -4.21
Mind Medicine (MindMed) Competitors $235.04 million -$90.94 million -7.67

Mind Medicine (MindMed)’s rivals have higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings for Mind Medicine (MindMed) and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mind Medicine (MindMed) 0 0 2 0 3.00
Mind Medicine (MindMed) Competitors 260 655 652 24 2.28

Mind Medicine (MindMed) currently has a consensus price target of 8.00, suggesting a potential upside of 725.25%. As a group, “Medicinals & botanicals” companies have a potential upside of 80.26%. Given Mind Medicine (MindMed)’s stronger consensus rating and higher probable upside, equities analysts plainly believe Mind Medicine (MindMed) is more favorable than its rivals.

Institutional and Insider Ownership

10.8% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 17.4% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 23.0% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

About Mind Medicine (MindMed) (Get Rating)

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.